Mortality Among People With HIV Treated for Tuberculosis Based on Positive, Negative, or No Bacteriologic Test Results for Tuberculosis: The IeDEA Consortium.
HIV
adults
epidemiology
mortality
tuberculosis
Journal
Open forum infectious diseases
ISSN: 2328-8957
Titre abrégé: Open Forum Infect Dis
Pays: United States
ID NLM: 101637045
Informations de publication
Date de publication:
Jan 2020
Jan 2020
Historique:
received:
11
09
2019
accepted:
08
01
2020
entrez:
4
2
2020
pubmed:
6
2
2020
medline:
6
2
2020
Statut:
epublish
Résumé
In resource-constrained settings, many people with HIV (PWH) are treated for tuberculosis (TB) without bacteriologic testing. Their mortality compared with those with bacteriologic testing is uncertain. We conducted an observational cohort study among PWH ≥15 years of age initiating TB treatment at sites affiliated with 4 International epidemiology Databases to Evaluate AIDS consortium regions from 2012 to 2014: Caribbean, Central and South America, and Central, East, and West Africa. The exposure of interest was the TB bacteriologic test status at TB treatment initiation: positive, negative, or no test result. The hazard of death in the 12 months after TB treatment initiation was estimated using a Cox proportional hazard model. Missing covariate values were multiply imputed. In 2091 PWH, median age 36 years, 53% had CD4 counts ≤200 cells/mm There was some evidence that PWH treated for TB with no bacteriologic test results were at higher risk of death than those with positive tests. Research is needed to understand the causes of death in PWH treated for TB without bacteriologic testing.
Sections du résumé
BACKGROUND
BACKGROUND
In resource-constrained settings, many people with HIV (PWH) are treated for tuberculosis (TB) without bacteriologic testing. Their mortality compared with those with bacteriologic testing is uncertain.
METHODS
METHODS
We conducted an observational cohort study among PWH ≥15 years of age initiating TB treatment at sites affiliated with 4 International epidemiology Databases to Evaluate AIDS consortium regions from 2012 to 2014: Caribbean, Central and South America, and Central, East, and West Africa. The exposure of interest was the TB bacteriologic test status at TB treatment initiation: positive, negative, or no test result. The hazard of death in the 12 months after TB treatment initiation was estimated using a Cox proportional hazard model. Missing covariate values were multiply imputed.
RESULTS
RESULTS
In 2091 PWH, median age 36 years, 53% had CD4 counts ≤200 cells/mm
CONCLUSIONS
CONCLUSIONS
There was some evidence that PWH treated for TB with no bacteriologic test results were at higher risk of death than those with positive tests. Research is needed to understand the causes of death in PWH treated for TB without bacteriologic testing.
Identifiants
pubmed: 32010735
doi: 10.1093/ofid/ofaa006
pii: ofaa006
pmc: PMC6984675
doi:
Types de publication
Journal Article
Langues
eng
Pagination
ofaa006Subventions
Organisme : NCATS NIH HHS
ID : UL1 TR000445
Pays : United States
Organisme : NIAID NIH HHS
ID : U01 AI096299
Pays : United States
Organisme : NIAID NIH HHS
ID : K08 AI104352
Pays : United States
Organisme : NIAID NIH HHS
ID : U01 AI096186
Pays : United States
Organisme : NIAID NIH HHS
ID : U01 AI069923
Pays : United States
Organisme : NIA NIH HHS
ID : R21 AG059505
Pays : United States
Organisme : NIAID NIH HHS
ID : U01 AI069911
Pays : United States
Organisme : NIAID NIH HHS
ID : U01 AI069919
Pays : United States
Organisme : NHLBI NIH HHS
ID : U01 HL146204
Pays : United States
Informations de copyright
© The Author(s) 2020. Published by Oxford University Press on behalf of Infectious Diseases Society of America.
Références
BMC Public Health. 2009 Nov 12;9:409
pubmed: 19909501
AIDS. 2001 Jan 26;15(2):143-52
pubmed: 11216921
Trans R Soc Trop Med Hyg. 2016 Aug;110(8):432-44
pubmed: 27638038
Lancet Infect Dis. 2018 Mar;18(3):261-284
pubmed: 29223583
Emerg Microbes Infect. 2018 Jun 6;7(1):102
pubmed: 29872046
Ethiop J Health Sci. 2017 Feb;27(Suppl 1):29-38
pubmed: 28465651
Int J Tuberc Lung Dis. 2011 Oct;15(10):1390-6
pubmed: 22283900
Int J Infect Dis. 2015 Mar;32:46-9
pubmed: 25809755
Lancet. 2014 Feb 1;383(9915):424-35
pubmed: 24176144
Ann Intern Med. 1992 Feb 15;116(4):320-8
pubmed: 1733389
PLoS One. 2013 Oct 17;8(10):e77697
pubmed: 24147059
Clin Microbiol Rev. 2011 Apr;24(2):314-50
pubmed: 21482728
PLoS One. 2016 Jan 25;11(1):e0147933
pubmed: 26808299
J Biomed Inform. 2009 Apr;42(2):377-81
pubmed: 18929686
BMC Public Health. 2008 Jan 14;8:15
pubmed: 18194573
PLoS One. 2013 Jun 06;8(6):e65421
pubmed: 23762367
J Acquir Immune Defic Syndr. 2012 Jan 1;59(1):25-30
pubmed: 22027877
PLoS One. 2014 Dec 02;9(12):e114225
pubmed: 25460363
Lancet. 2007 Jun 16;369(9578):2042-2049
pubmed: 17574096
Afr J Lab Med. 2017 Mar 31;6(2):519
pubmed: 28879164
Int J Tuberc Lung Dis. 2019 Mar 1;23(3):306-314
pubmed: 30871661
AIDS. 2015 Sep 24;29(15):1987-2002
pubmed: 26266773
Int J Tuberc Lung Dis. 2002 Mar;6(3):222-30
pubmed: 11934140
Int J STD AIDS. 2012 Sep;23(9):e1-4
pubmed: 23033530
PLoS One. 2017 Nov 16;12(11):e0188235
pubmed: 29145454
Clin Epidemiol. 2011 Jan 19;3:21-9
pubmed: 21326656
J Acquir Immune Defic Syndr. 2016 Aug 15;72(5):e86-91
pubmed: 27159224
Stat Methods Med Res. 2007 Jun;16(3):219-42
pubmed: 17621469
Clin Infect Dis. 2019 Oct 20;:null
pubmed: 31629369
PLoS One. 2017 Feb 9;12(2):e0171384
pubmed: 28182705
PLoS One. 2012;7(9):e45704
pubmed: 23049842
Malawi Med J. 2002 Sep;14(2):13-4
pubmed: 27528932
J Infect. 2007 Dec;55(6):502-9
pubmed: 17920686
Int J Epidemiol. 2012 Oct;41(5):1256-64
pubmed: 21593078
Trans R Soc Trop Med Hyg. 1999 Jul-Aug;93(4):443-6
pubmed: 10674100
PLoS One. 2016 Apr 13;11(4):e0153243
pubmed: 27073928
Int J Tuberc Lung Dis. 2011 Jul;15(7):871-85
pubmed: 21496360
Int J Tuberc Lung Dis. 2008 Sep;12(9):1042-7
pubmed: 18713502
Eur J Epidemiol. 2006;21(9):715-21
pubmed: 17072539
J Clin Epidemiol. 2008 Apr;61(4):344-9
pubmed: 18313558
Open Forum Infect Dis. 2014 Jun 25;1(1):ofu038
pubmed: 25734106
Int J Tuberc Lung Dis. 2001 Sep;5(9):847-54
pubmed: 11573897
AIDS. 1997;11 Suppl B:S115-23
pubmed: 9416373
Lancet. 2011 Apr 30;377(9776):1495-505
pubmed: 21507477
Int J Tuberc Lung Dis. 2001 Feb;5(2):113-22
pubmed: 11258504
Int J Tuberc Lung Dis. 2012 Sep;16(9):1199-204
pubmed: 22871326
Int J Infect Dis. 2009 Nov;13(6):722-9
pubmed: 19196530
Lancet Infect Dis. 2019 Mar;19(3):298-307
pubmed: 30744962
PLoS Med. 2012;9(7):e1001270
pubmed: 22911011
BMC Infect Dis. 2018 Apr 10;18(1):168
pubmed: 29636023
Pan Afr Med J. 2015 Nov 18;22:253
pubmed: 26958116
PLoS One. 2016 Aug 18;11(8):e0160481
pubmed: 27536864
BMC Public Health. 2014 Mar 29;14:289
pubmed: 24679187
West Afr J Med. 1999 Oct-Dec;18(4):270-4
pubmed: 10734790
J Acquir Immune Defic Syndr. 2012 Oct 1;61(2):216-20
pubmed: 22732465